交易 Taysha Gene Therapies Inc - TSHA 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.05
• 长仓隔夜仓息调整: -0.02146%
• 短仓隔夜仓息调整: -0.00076%
• 隔夜调整仓息时间: 21:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 5.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 6.49
• 开仓: 6.53
• 1 年变化: 167.62%
• 日区间: 6.53 - 7.02

交易 Taysha Gene Therapies Inc - TSHA 差价合约

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.